News

Further STEMI progress requires new focus

Publish date: January 24, 2013

 

EXPERT OPINION FROM THE ANNUAL CARDIOVASCULAR CONFERENCE AT SNOWMASS

Dr. Gersh reported that he serves as a consultant to Abbott, Boston Scientific, GE Healthcare, and other companies.

b.jancin@elsevier.com

Pages

Recommended Reading

Chelation Trial: Results Positive but Not Practice Changing
MDedge Internal Medicine
Stem Cell Treatment Post PCI Didn't Improve Outcomes
MDedge Internal Medicine
Fine-Tuning Therapeutic Hypothermia After Cardiac Arrest
MDedge Internal Medicine
Troponin Guidelines Sort Out When to Order, How to Read
MDedge Internal Medicine
New Strategy Distinguishes Inferior STEMI from Pericarditis
MDedge Internal Medicine
Survival After In-Hospital Cardiac Arrest Has Improved Substantially
MDedge Internal Medicine
Guidelines Update Approaches to Stable Ischemic Heart Disease
MDedge Internal Medicine
Prasugrel's use grows, but often off label
MDedge Internal Medicine
ED syncope observation protocol safely saves money
MDedge Internal Medicine
Hospital readmissions under attack
MDedge Internal Medicine